CR 666
Alternative Names: CR666; FE 200666Latest Information Update: 12 Feb 2015
At a glance
- Originator Ferring Pharmaceuticals; Freie Universitat Berlin
- Developer ALZA Corporation
- Class Analgesics
- Mechanism of Action Opioid kappa receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 10 Feb 2015 Cara Therapeutics has patent protection for κ opioid receptor agonists in USA
- 05 Jan 2006 CR 666 licensed to Cara Therapeutics worldwide
- 30 May 2002 Discontinued - Preclinical for Pain in Germany (unspecified route)